Document Detail


Modulating the nitric oxide - cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension.
MedLine Citation:
PMID:  20939842     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Group II pulmonary hypertension (PH) commonly occurs in the setting of a pressure-overloaded left ventricle (LV) which is also conducive to the development of heart failure with preserved ejection fraction. Population trends and a high prevalence of underlying causative conditions, such as essential hypertension or aortic stenosis, have increased the awareness of the pressure-overloaded LV and associated group II pulmonary hypertension. Patients often exhibit poor exercise tolerance and signs of heart failure indistinguishable from systolic heart failure; but effective medical treatments in this area have been lacking. Recent preclinical work has shed light on how the down-regulated nitric oxide - cyclic GMP pathway (within the myocardium and pulmonary vasculature) contributes to the pathophysiology of these associated conditions. This article will discuss the impact of the nitric oxide - cyclic GMP pathway on the pathogenesis of the pressure-overloaded LV and group II pulmonary hypertension, and will also introduce the potential therapeutic value of modulating this pathway.
Authors:
B R Lindman; M M Chakinala
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  International journal of clinical practice. Supplement     Volume:  -     ISSN:  1368-504X     ISO Abbreviation:  Int J Clin Pract Suppl     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-13     Completed Date:  2011-02-03     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  9712380     Medline TA:  Int J Clin Pract Suppl     Country:  England    
Other Details:
Languages:  eng     Pagination:  15-22     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Affiliation:
Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / therapeutic use
Aortic Valve Stenosis / physiopathology
Cardiomyopathies / physiopathology
Cyclic GMP / metabolism*
Cyclic Nucleotide Phosphodiesterases, Type 5 / metabolism
Diastole / physiology
Heart Failure / physiopathology,  therapy
Humans
Hypertension, Pulmonary / drug therapy,  physiopathology*
Hypertrophy, Left Ventricular / physiopathology*
Nitric Oxide / metabolism*
Oxidative Stress / physiology
Phosphodiesterase 5 Inhibitors / pharmacology
Signal Transduction / physiology
Stroke Volume / physiology
Systole / physiology
Ventricular Dysfunction, Left / physiopathology
Ventricular Remodeling / physiology
Grant Support
ID/Acronym/Agency:
KL2 RR024994-01/RR/NCRR NIH HHS; UL1 RR024992-01/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Phosphodiesterase 5 Inhibitors; 10102-43-9/Nitric Oxide; 7665-99-8/Cyclic GMP; EC 3.1.4.35/Cyclic Nucleotide Phosphodiesterases, Type 5
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man.
Next Document:  How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?